Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 21, 2024
Emerging Company Profile
Crossbow: Tumor antigen targeting beyond cell surface proteins, at scale
Through antibody targeting of HLA-peptide complexes, the MPM-built biotech is turning intracellular tumor antigens into handles for T cell engagers
BioCentury | Jan 27, 2022
Regulation
Immunocore charts path to broader indications, new targets after first FDA approval
Kimmtrak authorization brings the first uveal melanoma therapy and a new immuno-oncology modality to market
BioCentury | Dec 31, 2020
Distillery Therapeutics
Combining cholesterol metabolism inhibition with T cell therapy for glioblastoma, melanoma
DISEASE CATEGORY: Cancer
INDICATION: Brain cancer; melanoma Tethering T cell therapies to an inhibitor of the cholesterol metabolism enzyme SOAT could enhance the cell therapy’s efficacy
INDICATION: Brain cancer; melanoma Tethering T cell therapies to an inhibitor of the cholesterol metabolism enzyme SOAT could enhance the cell therapy’s efficacy
BioCentury | Dec 1, 2020
Product Development
Moderna moves & Immunocore breaks through: a BioCentury podcast
After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so
BioCentury | Nov 23, 2020
Product Development
Immunocore charts the path for bispecifics in solid tumors with Phase III readout
With a positive Phase III readout in metastatic uveal melanoma, Immunocore has become the first company to solve one of the biggest challenges in immuno-oncology: applying T cell-engaging bispecifics
BioCentury | Jun 1, 2019
Product Development
ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts
BioCentury’s analysis of ASCO 2019 abstracts shows bispecifics outpacing CAR Ts in solid tumors
BioCentury | Dec 21, 2018
Product R&D
Cell therapies seek solid ground
How mosaic antigen expression makes solid tumors hard nuts to crack
BioCentury | Jun 1, 2018
Clinical News
Immunocore reports Phase I/II data for uveal melanoma candidate
Items per page:
1 - 10 of 36